This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Reyes Gaido, O. E. et al. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci. Transl. Med. 15, eabq7839 (2023)
Related article
Abdelsayed, M. et al. Repurposing drugs to treat cardiovascular disease in the era of precision medicine. Nat. Rev. Cardiol. 19, 751–764 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huynh, K. Ruxolitinib is a CaMKII inhibitor that can be repurposed to prevent arrhythmias. Nat Rev Cardiol 20, 580 (2023). https://doi.org/10.1038/s41569-023-00910-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-023-00910-1
This article is cited by
-
Pathophysiology and clinical relevance of atrial myopathy
Basic Research in Cardiology (2024)